Ozolan (Anastrozole)

Anastrozole, the active ingredient in Ozolan, is an aromatase inhibitor presented as a 1 mg tablet for oral use. It is used in hormone‑dependent breast cancer treatment in post‑menopausal women. GNH USA supplies Ozolan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Ozolan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Anastrozole is employed in the management of estrogen‑driven conditions, primarily focusing on breast cancer pathways.

- Early‑stage hormone‑receptor‑positive breast cancer: helps ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ reduce ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  tumor growth. - Advanced or metastatic hormone‑receptor‑positive breast cancer: slows ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  disease progression. - Prevention of breast cancer recurrence after surgery: lowers ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  risk of new tumor development.

Adverse reactions to anastrozole are generally mild to moderate and reflect its hormonal modulation.

Common Side Effects: - Hot flashes - Joint or muscle pain - Fatigue - Nausea - Headache - Weight gain

Serious or Rare Side Effects: - Osteoporosis or decreased bone mineral density - Severe allergic reaction (anaphylaxis) - Elevated liver enzymes - Deep vein thrombosis or pulmonary embolism - Cardiovascular events such as myocardial infarction

When using Ozolan, certain safety measures and monitoring practices are recommended.

- Baseline bone health assessment: evaluate bone mineral density before initiating therapy. - Periodic liver function tests: monitor hepatic enzymes during treatment. - Cardiovascular risk evaluation: assess history of thromboembolic events. - Concomitant hormone therapy: avoid use with estrogen‑containing products. - Pregnancy and lactation: contraindicated; ensure effective contraception. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Anastrozole may interact with several medicines that influence hormone metabolism or share elimination pathways.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce anastrozole exposure. - Estrogen‑containing hormone replacement therapy – antagonises therapeutic effect.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, itraconazole) – may increase plasma levels. - Warfarin – potential alteration of anticoagulant effect. - Selective serotonin reuptake inhibitors (SSRIs) – possible additive effect on bone density loss.